April 24, 2013
Dr. Miguel Forte will present at the 19th ISCT Annual Meeting
"One year multiple injections of antigen specific T regulatory lymphocytes in refractory Crohn's disease patients, extension of CATS1 study"
P. Desreumaux et all.
Treg: Regulatory T Cells and T Helper Cells
TxCell has developed a unique proprietary, breakthrough technology platform, using type 1 regulatory T cells (link).
TxCell is dedicated to the development of therapeutic products for severe chronic inflammatory and autoimmune diseases with high unmet medical need including inflammatory bowel diseases, inflammatory joint diseases and neurological diseases such as Multiple Sclerosis.
The product candidates developed by TxCell consist of antigen-specific Type 1 regulatory cells (Ag-Tregs) generated ex-vivo from patient's peripheral blood in a proprietary manufacturing process (link).
Our lead product candidate, Ovasave, has completed a PI/II clinical trial in Crohn's disease patients, refractory to all current treatments (link). An international PIIb clinical trial is planned to confirm the positive PI/II study results.
New product candidates for other indications like rheumatoid arthritis and multiple sclerosis are in preclinical development.